BioMarin Pharmaceutical Inc.
NASDAQ: BMRN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander Hardy
- Employees
- 3,040
- Headquarters
- San Rafael, United States
- IPO year
- 1999
- Market cap
- $10.6B
- Website
- https://www.biomarin.com
Loading BMRN…
Loading profile data…Frequently asked questions about BMRN
What does BioMarin Pharmaceutical Inc. (BMRN) do?
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosi...
Where does BMRN trade?
BioMarin Pharmaceutical Inc. (BMRN) trades on the NASDAQ Global Select.
What sector is BMRN in?
BioMarin Pharmaceutical Inc. (BMRN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioMarin Pharmaceutical Inc.?
Alexander Hardy is the chief executive officer of BioMarin Pharmaceutical Inc. (BMRN).
Where is BioMarin Pharmaceutical Inc. headquartered?
BioMarin Pharmaceutical Inc. is headquartered in United States.
Does BMRN pay a dividend?
BioMarin Pharmaceutical Inc. (BMRN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BMRN go public?
BioMarin Pharmaceutical Inc. (BMRN) completed its initial public offering in 1999.